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ABSTRACT 
 
Benznidazole, a drug with specific anti-Trypanosoma cruzi activity, is used in the treatment of Chagas’ disease. The 
radiopharmaceutical sodium pertechnetate (Na99mTcO4) is used to obtain diagnostic images of the stomach, thyroid, 
parathyroids, salivary glands, brain and in the study of esophageal reflux and blood flow. This study aimed at 
evaluating in vivo the influence of benznidazole treatment on the sodium pertechnetate biodistribution in Wistar 
rats. The percentage of radioactivity per gram (%ATI/g) of various organs (brain, heart, esophagus, stomach, small 
intestine, large intestine, spleen, liver, muscle and blood) was determined. Comparing the treated rats with the 
controls, we observed that sodium pertechnetate biodistribution did not change when administered to rats treated 
for thirty days with benznidazole. 
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INTRODUCTION 
 
Chagas' disease is an endemic disorder caused by 
the flagellate protozoan Trypanosoma cruzi. It is a 
serious medical and social problem in Brazil and 
several Latin American countries, affecting 18 
million individuals, with 300 thousand new cases 
every year (WHO, 2002). T. cruzi can invade 
multiple host cells, generating megacolon, 
megaesophagus and chagasic heart disease (Santos 
et al., 2005; Texeira et al., 2006). Benznidazole 
(Bz), commercially known as Rochagan®, is a 
drug with specific anti-T. cruzi activity in vivo and 
in vitro, available in Brazil since the 1970s (Coura 
and Castro, 2002). It contains N-benzyl-2-nitro-1-
imidazolacetamida, which acts directly on the 
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macromolecule synthesis by a covalent link with 
cellular components. It has demonstrated low 
efficiency and high toxicity, especially in the 
chronic phase of the disease and its treatment can 
last for up to 60 days, depending on clinical 
manifestations and host tolerance (Cançado, 
2005).  
The most widely used treatment scheme is 10 
mg/kg/day in adults and less than 5 mg/kg/day in 
children (Castro et al., 2000; Cançado, 2002; 
Urbina and Docampo, 2003; Dias, 2004). 
Following oral administration, Bz is absorbed by 
the intestine, and is bound to plasma proteins and 
red blood cells to be distributed throughout the 
body. Maximum plasma concentrations are 
achieved in two to four hours. The half-life of 
plasma elimination is approximately twelve hours 
(Morilla et al., 2005). 
Among the many diagnostic tools that can be used 
in tropical diseases, scintigraphy is widely used in 
the anatomic and functional analyses of organs and 
systems (Braga, 2002). Technetium-99m (99mTc), 
in the form of sodium pertechnetate (Na99mTcO4), 
is a radionuclide that connects to a wide variety of 
molecules and cells (Thrall and Ziessman, 2003; 
Saha, 2004). When injected intravenously, it is 
distributed through the veins and interstitium and 
is used to obtain diagnostic images of the stomach, 
thyroid, parathyroids, salivary glands, brain and in 
the study of esophageal reflux and blood flow 
(Saha, 2004; Owunwanne et al., 1995; Thrall and 
Ziessman, 2003).  
Several drugs can interfere with the biological 
behavior of radiopharmaceuticals used in 
scyntigraphic examinations. They can change the 
biological effect of the radiopharmaceutical and 
their interaction can lead to hypo or hyper uptake 
of radiopharmaceuticals in a particular organ, 
causing incorrect diagnosis or misinterpretation of 
results. Repeated scintigraphy may result in 
unnecessary radiation for patients (Bernardo-Filho 
et al., 2005; Gomes et al., 2002). Although Bz is 
the drug currently recommended by the National 
Foundation of Health, Brazil, and is used by 
thousands of people, little is known about its 
action mechanism, its effects on host cells or its 
toxicity. Thus, it is important to study the effect of 
Bz on the biodistribution of the 
radiopharmaceutical sodium pertechnetate in 
laboratory animals subjected to chronic treatment  
with this drug. The aim of this work was to assess  
in vivo the influence of Bz on the biodistribution 
of sodium pertechnetate in rats. 
 
 
MATERIALS AND METHODS 
 
Twelve male Wistar rats weighing 200-250g from 
the Centro de Ciências da Saúde, Universidade 
Federal do Rio Grande do Norte (UFRN), Natal–
RN, Brazil were used. The protocol was conducted 
in accordance with Brazilian College of Animal 
Experimentation guidelines and was approved by 
the Research Ethics Committee of Onofre Lopes 
Hospital-UFRN (08/2007). The animals had free 
access to water and standard food for rodents 
(Labina Purina ®) and were randomly allocated to 
2 groups: control and treated. The treated group 
(n=6) received 5 mg/kg/day of Bz diluted with 
sorbitol, by gavage. The control rats (n=6) 
received only sorbitol. The animals were treated 
for 30 days. On the last day of treatment the rats 
received 0.1 mL of Na99mTcO4 (3.7 MBq) via 
orbital plexus. 
The Na99mTcO4 was eluted in a 99Mo/99mTc 
generator (Instituto de Pesquisas Energéticas e 
Nucleares, São Paulo, Brazil). After 60 minutes, 
all animals were quickly killed under anesthesia 
with xylazine (20 mg/kg) and ketamine (50 mg/ 
kg), by intraperitoneal via. Samples were 
harvested from the brain, heart, esophagus, 
stomach, small intestine, large intestine, spleen, 
liver, muscle and blood. The tissue samples were 
washed in 0.9% saline, weighed on a precision 
scale (Mark 160®, Bel equipment, Italy) and the 
percentage of radioactivity per gram of tissue 
(%ATI/g) was determined in an automatic gamma 
counter (Wizard 1470, Perkin-Elmer, Finland). 
The efficiency of the gamma counter was 86%, as 
specified by the manufacturer. The biochemical 
and hematological dosages were performed in 
automated equipment TermoKonelab 60i, Abbot 
and Cell-Dyn 3500R, Abbot, respectively. Data 
were presented as mean ± standard deviation. The 
percentage of radioactivity per gram (%ATI/g) 
was determined by dividing the percentage of total 
radioactivity of each sample by its weight in 
grams. The ATI%/g was compared using the non-
parametric Mann-Whitney test and the 
biochemical and hematological parameters by 
Student’s t-test, considering the level of statistical 
significance at p<0.05 in both tests. Statistica 6.0 
software was used. 
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RESULTS 
 
Table 1 shows the relationship between the 
controls and the Bz-treated rats. No statistically 
significant difference (p>0.05) in biodistribution 
of sodium pertechnetate was observed in any of 
the organs. 
Table 2 shows significant differences in alanine 
aminotransferase (ALT) dosage and the percentage 
of neutrophils and lymphocytes, when comparing 
the treated and control rats. All the other 
parameters such as iron, total protein, 
aminotransferase aspartate (AST), creatinine, 
glucose, red blood cells, hemoglobin, hematocrit, 
white blood cells and platelets showed no 
significant differences, when the two groups were 
compared (p>0.05). 
Table 1 - Effect of benznidazole treatment on Na99mTcO4 biodistribution in Wistar rats. 
% ATI Organs 
 Controls Treated 
Spleen 0.00211 ± 0.00076 0.00199 ± 0.00039 
Brain 0.00175 ± 0.00392 0.00020 ± 0.00007 
Heart 0.00158 ± 0.00039 0.00192 ± 0.00053 
Esophagus 0.00349 ± 0.00123 0.00330 ± 0.00084 
Stomach 0.02576 ± 0.00761 0.02276 ± 0.01016 
Liver 0.00379 ± 0.00105 0.00402 ± 0.00080 
Small Intestine 0.00390 ± 0.00132 0.00299 ± 0.00169 
Large Intestine 0.00149 ± 0.00071 0.00163 ± 0.00043 
Muscle 0.00050 ± 0.00011 0.00063 ± 0.00014 
Blood 0.00683 ± 0.00158 0.00811 ± 0.00165 
Mean ± SD. No difference was observed between the two groups (p>0.05). 
 
 
Table 2 - Effect of benznidazole treatment on biochemical and hematological parameters. 
Groups Biochemical and hematological 
dosages Controls Treated 
Iron (µg/L) 363.0 ± 24.69 308.5 ± 65.56 
Total proteins (g/dL) 6.50 ± 0.303 6.55 ± 0.327 
ALT (UI/L) 116.0 ± 32.44 98.2 ± 23.60 
AST (UI/L) 73.16 ± 8.495 56.66* ± 9.667 
Creatinine (mg/dL) 0.375 ± 0.055 0.381 ± 0.040 
Glucose (mg/dL) 122.000 ± 19.193 117.666 ± 10.557 
Red blood cells (u/mm3) 6653333 ± 372487.1 6578333 ± 526931.4 
Neutrophils (%) 57.5 ± 2.949 34.0* ± 8.786 
Lymphocytes (%) 34.5 ± 2.428 58.6* ± 7.890 
Hemoglobin (g/%) 12.183 ± 0.598 11.450 ± 0.831 
Hematocrit (%) 52.133 ± 3.669 51.616 ± 3,023 
Platelets (u/mm3) 716833.3 ± 14770.47 718333.3 ± 00059.32 
Leukocytes (u/mm3) 3195.0 ± 1126.7 2206.6 ± 646.3 
Mean±SD . *, p<0.05. 
 
 
DISCUSSION 
 
The biological behavior of radiopharmaceuticals 
used for diagnosis in nuclear medicine is well 
established in the scientific literature. The 
interaction between a drug and a 
radiopharmaceutical may alter its biodistribution 
and result in an unexpected effect (Gomes et al., 
2002, Bernardo-Filho et al., 2005).  
It is of critical importance to know which drugs 
can interfere with the normal biodistribution of 
radiopharmaceuticals, to avoid the 
misinterpretation of scintigraphic images. Several 
authors have shown that radiopharmaceutical 
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biodistribution can be altered by natural and 
synthetic products, radiotherapy, surgery and diet 
(Gomes et al., 2002; Xavier-Holanda et al., 2002; 
Passos et al, 2002; Bernardo et al., 2004; Moreno 
et al., 2005; Santos-Filho and Bernardo-Filho., 
2005; Holanda et al., 2006; Araújo-Filho et al., 
2007). 
Glucantime, an anti-Leishmania drug, increased 
the uptake of the radiopharmaceutical methylene 
disphosphonic acid, labeled with technetium-99m 
(99mTc-MDP) in the spleen, kidney, testicles, heart 
and liver of rats (Xavier-Holanda et al., 2002). The 
biodistribution of 99mTc-MDP was also changed in 
various organs of rats treated with the 
antimalarials artemisinin and mefloquine (Holanda 
et al., 2006). Araujo-Filho et al. (2007) reported 
changes in sodium pertechnetate biodistribution in 
the thyroid, lung, pancreas, spleen and muscle 
after biliopancreatic bypass surgery with duodenal 
switch in rats. Moreno et al. (2005) showed that 
Ginkgo biloba extract can change the sodium 
pertechnetate biodistribution in the kidneys, liver 
and duodenum. Santos-Filho and Bernardo-Filho. 
(2005) showed that Hypericum perforatum extract 
reduced the uptake of the radiopharmaceutical in 
bone, muscle and thyroid.  
Some studies show that Bz can have adverse 
effects on adrenal cortex, esophagus and colon 
cells in rats and that it exerts a mutagenic and 
carcinogenic effect (Diaz, 2000, Castro et al., 
2006, de Castro et al., 2003). Because of its 
antigenic and toxic effect, Bz can cause several 
undesirable reactions, mainly in the nervous 
system and gastrointestinal tract (Cançado, 2002). 
During benznidazole treatment (30 to 60 
consecutive days), skin reactions, gastrointestinal 
disorders, nausea, paresthesia, or symptoms of 
peripheral polyneuritis may occur, especially after 
prolonged treatment or with excessive doses of Bz. 
The depression of the bone marrow with 
neutropenia, thrombocytopenic purple and 
hepatotoxicity are serious effects of Bz that 
demand caution when they are being used 
(Cançado, 2005). In our study, neutropenia was 
found in Bz-treated rats, but no hepatic and 
intestinal mucous membrane damage was 
observed. Although Bz can cause these several 
undesirable reactions, our results were shown 
positive in relation to interaction Bz-
radiopharmaceutical. Both Bz and sodium 
pertechnetate are bound to plasma proteins, but it 
seems that there is no competition between them 
for the same connection sites (Coura and Castro, 
2002; Owunwanne et al., 1995). Bz also, probably, 
does not interfere in the intestinal mobility and 
does not alter blood flow. The alteration of these 
factors could modify the biodistribution of the 
radiopharmaceutical (Owunwanne et al., 1995). 
Data from biochemical and hematological 
parameters also lead us to believe that Bz, 
administered in equivalent dose to treat Chagas' 
disease in humans, had no toxic effect on the 
organs studied, nor did it cause enough tissue 
damage to promote a change in the uptake of 
Na99mTcO4.  
In this study we demonstrated that the 
administration of benznidazole didn't alter sodium 
pertechnetate biodistribution to important target 
organs, what demonstrate that this result is 
satisfactory for its use in patients with Chagas’ 
disease. In spite of, this experimental were 
performed in Wistar rats. 
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RESUMO 
 
O benzonidazol é um quimioterápico com 
atividade específica anti-T. cruzi utilizado por 
milhares de pessoas para tratamento da doença de 
Chagas. O radiofármaco pertecnetato de sódio 
(Na99mTcO4) é utilizado na obtenção de imagens 
diagnósticas do estômago, tireóide, paratireóides, 
glândulas salivares, plexo coróide, cérebro e de 
estudos de refluxo esofágico e de fluxo sanguíneo. 
Esse trabalho objetivou avaliar in vivo a influência 
do tratamento crônico com o benzonidazol na 
biodistribuição do radiofármaco pertecnetato de 
sódio em ratos Wistar. O percentual de 
radioatividade por grama (%ATI/g) de vários 
órgãos (cérebro, coração, esôfago, estômago, 
intestino delgado, intestino grosso, baço, fígado, 
músculo e sangue) foi determinado. Comparando-
se o grupo controle e o tratado observou-se que o 
pertecnetato de sódio não possui sua 
biodistribuição alterada quando administrado em 
ratos tratados por trinta dias com a droga 
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benzonidazol, mostrando não prejudicar a 
interpretação de diagnósticos por imagem. 
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